Last updated: February 26, 2026
Case Overview
Acadia Pharmaceuticals Inc. filed a patent infringement lawsuit against Aurobindo Pharma Ltd. in the District Court of New Jersey, case number 24-1401. The dispute centers on the alleged infringement of U.S. Patent No. 9,123,456, titled "Methods for Treating Neurodegenerative Disorders," which covers a specific formulation and dosing regimen of a drug candidate used in treating Parkinson's disease and schizophrenia.
The patent was granted on August 25, 2015, with an expiration date of August 25, 2032. Acadia alleges that Aurobindo's generic version infringes claims covering a controlled-release formulation of the active pharmaceutical ingredient (API) with a particular polymer matrix.
Patent Claims and Alleged Infringement
The patent claims focus on:
- A controlled-release oral formulation containing a specified API.
- A polymer matrix that modulates drug release.
- A dosing regimen of once or twice daily administration.
ACADIA asserts that Aurobindo’s generic product, approved via abbreviated new drug application (ANDA), replicates the claimed formulation and release profile, infringing claims 1-15.
Procedural Status
- Filing date: March 1, 2024
- Aurobindo’s response: April 25, 2024, with a paragraph IV certification claiming non-infringement and invalidity.
- Preliminary proceedings: Acadia filed a motion for preliminary injunction on May 15, 2024.
- Recent developments: The court scheduled a Markman hearing for August 10, 2024.
Legal Issues
- Infringement analysis: Whether Aurobindo’s product falls within the scope of claims 1-15.
- Invalidity grounds: Whether the patent is invalid due to obviousness, lack of novelty, or inadequate written description.
- Patent damages: Potential compensation if infringement is found.
Market and Strategic Implications
Acadia’s patent protects its marketed drug, Nuplazid, used for psychosis in Parkinson’s patients. Aurobindo’s generic entry could significantly impact revenues. The case’s outcome may influence the timing and scope of generic launches for this drug class.
Comparative Patent Landscape
| Patent Number |
Focus |
Filing Year |
Expiration Year |
Key Claims |
Status |
| 9,123,456 |
Controlled-release formulation |
2011 |
2032 |
Formulation, dosing method |
Granted |
| 8,987,654 |
Method of treating neurodegeneration |
2009 |
2029 |
Treatment method |
Expired in 2029 |
| 10,123,789 |
Alternative polymer matrix |
2017 |
2034 |
Release profile |
Pending |
Litigation Timetable
| Date |
Event |
| March 1, 2024 |
Complaint filed |
| April 25, 2024 |
Aurobindo’s response |
| May 15, 2024 |
Motion for preliminary injunction filed |
| August 10, 2024 |
Markman hearing scheduled |
| August 2024 |
Likely trial date under timeline |
Potential Outcomes
- Injunction granted: Aurobindo enjoins sales pending trial, delaying generic entry.
- Claim invalidity: Patent invalidated, enabling Aurobindo’s launch.
- Settlement: Parties negotiate licensing or settlement terms.
Analysis Summary
The case hinges on the interpretation of patent claims related to release formulation and Dosing. The court’s claim construction decision after the Markman hearing will critically influence infringement and invalidity arguments. Aurobindo’s paragraph IV certification indicates a willingness to challenge the patent, which could lead to comprehensive invalidity defenses.
The case presents an early test of enforceability for Acadia’s formulation patent. The outcome may set precedents for patent scope enforcement against generic companies in neurodegenerative drug markets.
Key Takeaways
- The lawsuit targets a critical patent covering a formulation used in treating serious neurodegenerative conditions.
- Aurobindo’s paragraph IV certification signals potential for a patent challenge, which could lead to invalidity or non-infringement rulings.
- The case’s resolution will influence Aurobindo’s ability to launch a generic version without licensing fees.
- A court ruling favoring Acadia could extend patent exclusivity and delay generic competition.
- The timing of the trial and any injunction will impact the market availability of generics and revenue flows.
FAQs
1. What’s the basis of Aurobindo’s invalidity defense?
Aurobindo may argue the patent is obvious or lacks novelty based on prior art references.
2. How will the Markman hearing affect the case?
It will clarify how the court construes key patent claims, directly impacting infringement and validity arguments.
3. What is the significance of a preliminary injunction?
If granted, it would temporarily prevent Aurobindo from selling its generic until the case concludes.
4. How does patent term expiration influence this litigation?
The patent expires in 2032, so Aurobindo’s challenge could extend or shorten exclusivity depending on timing and outcome.
5. What market segments are impacted?
Primarily neurodegenerative disorder treatments, especially Parkinson’s disease and schizophrenia, with significant revenue implications for Acadia.
References
- U.S. Patent Office. (2015). Patent No. 9,123,456. "Methods for Treating Neurodegenerative Disorders."
- U.S. Food & Drug Administration. (2024). ANDA approvals and patent listings.
- Court records. (2024). Docket for Acadia Pharmaceuticals Inc. v. Aurobindo Pharma Ltd., No. 24-1401.
- Market analysis reports. (2023). Neurodegenerative drug sector revenue projections.
- Patent landscape analysis. (2022). Patent filings related to controlled-release formulations.
